| 1. |
- Röllig, M., et al.
(author)
-
A photon dominated region code comparison study
- 2007
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 467:No. 1 (May III 2007), s. 187-206
-
Journal article (peer-reviewed)abstract
- Aims.We present a comparison between independent computer codes, modeling the physics and chemistry of interstellar photon dominated regions (PDRs). Our goal was to understand the mutual differences in the PDR codes and their effects on the physical and chemical structure of the model clouds, and to converge the output of different codes to a common solution.Methods. A number of benchmark models have been created, covering low and high gas densities n = 103,105.5 cm-3 and far ultraviolet intensities $\chi$ = 10, 105 in units of the Draine field (FUV: 6
|
|
| 2. |
- Goicoechea, J.R., et al.
(author)
-
VELOCITY-RESOLVED [C II] EMISSION AND [C II]/FIR MAPPING ALONG ORION WITH HERSCHEL
- 2015
-
In: Astrophysical Journal. - 1538-4357 .- 0004-637X. ; 812:1, s. 75-
-
Journal article (peer-reviewed)abstract
- We present the first ~7.′5 × 11.′5 velocity-resolved (~0.2 km/s) map of the [C II] 158 μm line toward the Orion molecular cloud1 (OMC1) taken with the Herschel/HIFI instrument. In combination with far-IR (FIR) photometric images and velocity-resolved maps of the H41α hydrogen recombination and CO J = 2–1 lines, this data set provides an unprecedented view of the intricate small-scale kinematics of the ionized/photodissociation region (PDR)/molecular gas interfaces and of the radiative feedback from massive stars. The main contribution to the [C II] luminosity (~85%) is from the extended, FUV-illuminated face of the cloud (G0 > 500, nH > 5 × 10^3 cm^−3) and from dense PDRs (G0>~10^4, nH>~10^5 cm^−3) at the interface between OMC 1 and the H II region surrounding the Trapezium cluster. Around ~15% of the [C II] emission arises from a different gas component without a CO counterpart. The [C II] excitation, PDR gas turbulence, line opacity (from [13C II]), and role of the geometry of the illuminating stars with respect to the cloud are investigated. We construct maps of the L[CII]/LFIR and LFIR/MGas ratios and show that L[CII]/LFIR decreases from the extended cloud component (~10^−2–10^−3) to the more opaque star-forming cores (~10^-3-10−4). The lowest values are reminiscent of the “[C II] deficit” seen in local ultraluminous IR galaxies hosting vigorous star formation. Spatial correlation analysis shows that the decreasing L[C II]/LFIR ratio correlates better with the column density of dust through the molecular cloud than with LFIR/MGas. We conclude that the [C II]-emitting column relative to the total dust column along each line of sight is responsible for the observed L[C II]/LFIR variations through the cloud.
|
|
| 3. |
- Angenendt, Linus, et al.
(author)
-
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia : A Pooled Analysis of Individual Patient Data From Nine International Cohorts
- 2019
-
In: Journal of Clinical Oncology. - : AMER SOC CLINICAL ONCOLOGY. - 0732-183X .- 1527-7755. ; 37:29, s. 2632-2642
-
Journal article (peer-reviewed)abstract
- PURPOSE: Nucleophosmin 1 (NPM1) mutations are associated with a favorable prognosis in acute myeloid leukemia (AML) when an internal tandem duplication (ITD) in the fms-related tyrosine kinase 3 gene (FLT3) is absent (FLT3-ITDneg) or present with a low allelic ratio (FLT3-ITDlow). The 2017 European LeukemiaNet guidelines assume this is true regardless of accompanying cytogenetic abnormalities. We investigated the validity of this assumption.METHODS: We analyzed associations between karyotype and outcome in intensively treated patients with NPM1(mut)/FLT3-ITDneg/low AML who were prospectively enrolled in registry databases from nine international study groups or treatment centers.RESULTS: Among 2,426 patients with NPM1(mut)/FLT3-ITDneg/low AML, 2,000 (82.4%) had a normal and 426 (17.6%) had an abnormal karyotype, including 329 patients (13.6%) with intermediate and 83 patients (3.4%) with adverse-risk chromosomal abnormalities. In patients with NPM1(mut)/FLT3-ITDneg/low AML, adverse cytogenetics were associated with lower complete remission rates (87.7%, 86.0%, and 66.3% for normal, aberrant intermediate, and adverse karyotype, respectively; P < .001), inferior 5-year overall (52.4%, 44.8%, 19.5%, respectively; P < .001) and event-free survival (40.6%, 36.0%, 18.1%, respectively; P < .001), and a higher 5-year cumulative incidence of relapse (43.6%, 44.2%, 51.9%, respectively; P = .0012). These associations remained in multivariable mixed-effects regression analyses adjusted for known clinicopathologic risk factors (P < .001 for all end points). In patients with adverse-risk chromosomal aberrations, we found no significant influence of the NPM1 mutational status on outcome.CONCLUSION: Karyotype abnormalities are significantly associated with outcome in NPM1(mut)/FLT3-ITDneg/low AML. When adverse-risk cytogenetics are present, patients with NPM1(mut) share the same unfavorable prognosis as patients with NPM1 wild type and should be classified and treated accordingly. Thus, cytogenetic risk predominates over molecular risk in NPM1(mut)/FLT3-ITDneg/low AML.
|
|
| 4. |
- Dimopoulos, Meletios A., et al.
(author)
-
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010) : A phase 3b study in refractory multiple myeloma
- 2016
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 128:4, s. 497-503
-
Journal article (peer-reviewed)abstract
- Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients who failed treatment with bortezomib and lenalidomide and had adequate prior alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the primary end point; secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Among 682 patients enrolled, median age was 66 years, and median time since diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8 months; median duration of treatment was 4.9 months. Most frequent grade 3/4 treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic toxicities were pneumonia (10.9%) and fatigue (5.9%). Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6% each). The ORR was 32.6%, and the median DOR was 7.4 months. Median PFS and OS were 4.6 months and 11.9 months, respectively. We present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming that this regimen offers clinically meaningful benefit and is generally well tolerated. www.Clinicaltrials.gov identifier NCT01712789.
|
|
